Update (4:25 p.m.): Updated with Tuesday market close information.
But the stock plunged in the afternoon after TheStreet's Adam Feuerstein wrote CEO Joseph Kim is trying to curb expectations for the soon-to-be-announced results from its phase II study of its DNA vaccine VGX-3100 in women with cervical pre-cancerous lesions.
The stock closed down 13.36%, or $1.44, to $9.34. More than 11.3 million shares changed hands, which surpassed the average volume of 1,521,180.Must Read: Inovio CEO Preps Retail Investors for Drug Study Failure STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. For more on this story, read Feuerstein's article here. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts